Overview

A Study of BEZ235 in Adult Japanese Patients With Advanced Solid Tumors

Status:
Completed
Trial end date:
2013-07-01
Target enrollment:
Participant gender:
Summary
In this study, BEZ235 will be administered to adult patients with advanced solid tumors whose disease has progressed despite standard therapy or for whom no standard therapy exists. The trial will confirmed the safety and tolerability and determine the MTD of BEZ235 in Japanese patients.
Phase:
Phase 1
Details
Lead Sponsor:
Novartis Pharmaceuticals
Treatments:
Dactolisib